Assura PLC Development Update (8649G)
01 April 2022 - 5:01PM
UK Regulatory
TIDMAGR
RNS Number : 8649G
Assura PLC
01 April 2022
1 April 2022
Assura plc
Development update
Assura plc ("Assura"), the leading primary care property
investor and developer, today announces it has reached financial
close on a development funding agreement for a GBP31 million cancer
diagnostic and treatment centre in Guildford.
The building will be operated by and let to Genesis Cancer Care
UK Limited ("GenesisCare") on a 30-year FRI lease with annual,
index-linked rent reviews.
The building, situated adjacent to the Royal Surrey County
Hospital, will provide cutting-edge oncology and cancer care
services via a partnership agreement between GenesisCare and the
Royal Surrey NHS Foundation Trust. The cancer centre will house two
radiotherapy treatment bunkers (one state-of-the-art MR-guided
Linac and one conventional Linac) as well as diagnostic facilities
and a radiopharmacy facility for the provision of nuclear medicine
imaging and treatment.
The building is expected to achieve a BREEAM rating of Very
Good, with Excellent for the Energy component, and an EPC of A. The
building will include PV panels, LED lighting throughout and EV
charging points. The site will benefit from creation of a new
sensory garden for patient and staff wellbeing and we have also
introduced an education and skills bursary package as part of our
overall funding approach.
The centre is being developed by Prime and built by Vinci
Construction, with practical completion expected by Q4 2023.
Jonathan Murphy, CEO, said:
"We are pleased to be working with Prime again to forward fund
this scheme in Guildford. This new, state-of-the-art facility will
deliver services that ease the burden on the local NHS and help
create additional capacity within existing NHS assets to address
treatment backlogs.
"This scheme is another step on our strategy to expand our
offering, working with selected high-quality private providers who
partner with the NHS as well as having a high sustainability and
social impact."
- ENDS -
For more information, please contact:
Assura plc Tel: 01925 945354
David Purcell, Head of Investor Email: Investor@assura.co.uk
Relations
Finsbury Tel: 0207 251 3801
Gordon Simpson Email: Assura@finsbury.com
James Thompson
Notes to Editors
Assura plc, a constituent of the FTSE 250 and the EPRA* indices,
is a UK REIT and long-term investor in and developer of primary
care property. The company, headquartered in Warrington, works with
GPs, health professionals and the NHS to create outstanding spaces
for health services in our communities. At 30 September 2021,
Assura's property portfolio was valued at GBP2,595 million.
Further information is available at www.assuraplc.com
*EPRA is a registered trademark of the European Public Real
Estate Association.
Assura plc LEI code: 21380026T19N2Y52XF72
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTWPUPWWUPPPUG
(END) Dow Jones Newswires
April 01, 2022 02:01 ET (06:01 GMT)
Assura (LSE:AGR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assura (LSE:AGR)
Historical Stock Chart
From Apr 2023 to Apr 2024